New antibody drug HB0056 begins first human safety trial
NCT ID NCT06612970
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial is testing the safety of a single dose of HB0056, a new bispecific antibody, in 46 healthy adults aged 18 to 55. Participants are randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The study does not aim to treat any disease but to gather essential safety data before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB0056 (a bispecific antibody targeting TSLP and IL-11)
- What this could lead to
- If safe, this could pave the way for future studies of HB0056 in diseases involving inflammation or immune responses.
- What could go wrong
- This is an early Phase 1 trial in healthy people, so it won't show if the drug works for any disease. Side effects are possible and unknown yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Zealand Clinical Research
RECRUITINGChristchurch, 8011, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test